This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tacca, O. Articles by Chollet, P. Search for Related Content PubMed PubMed Citation Articles by Tacca, O. Articles by Chollet, P.

Breast Cancer

Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

^aCentre Jean Perrin, Clermont-Ferrand, France; ^bINSERM U484, Clermont-Ferrand, France; ^cUniversité d'Auvergne, Clermont-Ferrand, France; ^dCentre d'Investigation Clinique, Clermont-Ferrand, France; ^eInstitut Jean Godinot, Reims, France

Key Words. Hormone receptor status • Neoadjuvant chemotherapy • Breast cancer • Allred score

Correspondence: Correspondence: Olivier Tacca, Ph.D., Bureau de Recherche Clinique, Centre Jean Perrin 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 1, France. Telephone: 33-473278005; Fax: 33-473278029; e-mail: recherche.clinique{at}cjp.fr

The aim of this study was to detect and analyze changes in hormone receptor (HR) status after treatment of operable breast cancer with neoadjuvant chemotherapy (NCT). Patients were treated from 1982 to 2004 with different NCT combinations, mainly in successive prospective phase II trials. HR status before and after NCT was retested and reviewed in a blinded fashion by two pathologists, for 420 patients from a database of 710 patients. Among these 420 tumors, 145 (35%) were HR negative and 275 (65%) were HR positive before NCT. The HR status had changed after treatment in 98 patients (23%): 61 patients (42%) initially HR negative became HR positive. This HR-positive switch was significantly correlated with better overall survival (OS), compared with patients with unchanged HR-negative tumors. Moreover, this HR-positive switch also had an effect on disease-free survival (DFS). Conversely, 37 patients (13%) initially HR positive became HR negative after NCT. However, this group of previously positive patients still had a survival advantage for OS, but not for DFS. The Allred score was evaluated before and after chemotherapy. An increase in Allred score after NCT was significantly correlated with better DFS but not OS. It was previously shown, for other tumor parameters, that residual disease after NCT, rather than parameters evaluated on the initial biopsy, must be considered for patient prognosis. In this work, NCT induced variations in HR status in 23% of patients. A positive switch in HR status after NCT could be an indicator of better prognosis for patient outcome.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				P. S. Steeg Heterogeneity of Drug Target Expression Among Metastatic Lesions: Lessons from a Breast Cancer Autopsy Program Clin. Cancer Res., June 15, 2008; 14(12): 3643 - 3645. [Full Text] [PDF]